Literature DB >> 26357949

The Epidemiology of Anaphylaxis.

Joyce E Yu1, Robert Y Lin2.   

Abstract

Anaphylaxis is a dramatic expression of systemic allergy. The lifetime prevalence of anaphylaxis is currently estimated at 0.05-2 % in the USA and ~3 % in Europe. Several population-specific studies have noted a rise in the incidence, particularly in the hospitalizations and ER visits due to anaphylaxis. The variable signs and symptoms that constitute the diagnostic criteria for anaphylaxis, the differences in diagnostic algorithms, and the limitations in the current coding systems have made summarizing epidemiologic data and comparing study results challenging. Nevertheless, across all studies, the most common triggers continue to be medications, food, and venom. Various risk factors for more severe reactions generally include older age, history of asthma, and having more comorbid diseases. Interesting seasonal, geographic, and latitude differences have been observed in anaphylaxis prevalence and incidence rates, suggesting a possible role of vitamin D and sun exposure in modifying anaphylaxis risk. While the incidence and prevalence of anaphylaxis appear to be increasing in certain populations, the overall fatality rate remains relatively low.

Entities:  

Keywords:  Anaphylaxis; Biphasic; Epidemiology; Fatality; Incidence; Prevalence; Risk factor; Triggers

Mesh:

Substances:

Year:  2018        PMID: 26357949     DOI: 10.1007/s12016-015-8503-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  91 in total

Review 1.  Occupational anaphylaxis--an EAACI task force consensus statement.

Authors:  A Siracusa; I Folletti; R Gerth van Wijk; M F Jeebhay; G Moscato; S Quirce; M Raulf; F Ruëff; J Walusiak-Skorupa; P Whitaker; S M Tarlo
Journal:  Allergy       Date:  2015-02       Impact factor: 13.146

2.  Drug-induced anaphylaxis survey in Portuguese Allergy Departments.

Authors:  E Faria; J Rodrigues-Cernadas; A Gaspar; C Botelho; E Castro; A Lopes; E Gomes; D Malheiro; S Cadinha; S Campina-Costa; M Neto; N Sousa; R Rodrigues-Alves; A Romeira; J Caiado; M Morais-Almeida
Journal:  J Investig Allergol Clin Immunol       Date:  2014       Impact factor: 4.333

3.  First European data from the network of severe allergic reactions (NORA).

Authors:  M Worm; A Moneret-Vautrin; K Scherer; R Lang; M Fernandez-Rivas; V Cardona; M L Kowalski; M Jutel; I Poziomkowska-Gesicka; N G Papadopoulos; K Beyer; T Mustakov; G Christoff; M B Bilò; A Muraro; J O B Hourihane; L B Grabenhenrich
Journal:  Allergy       Date:  2014-08-16       Impact factor: 13.146

4.  Anaphylaxis to muscle relaxants: an audit of ten years of allergy testing at the Royal Adelaide Hospital.

Authors:  A Brereton; W J Russell
Journal:  Anaesth Intensive Care       Date:  2012-09       Impact factor: 1.669

Review 5.  Idiopathic anaphylaxis.

Authors:  Phil L Lieberman
Journal:  Allergy Asthma Proc       Date:  2014 Jan-Feb       Impact factor: 2.587

6.  Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland.

Authors:  Margitta Worm; Oliver Eckermann; Sabine Dölle; Werner Aberer; Kirsten Beyer; Thomas Hawranek; Stephanie Hompes; Alice Koehli; Vera Mahler; Katja Nemat; Bodo Niggemann; Claudia Pföhler; Uta Rabe; Angelika Reissig; Ernst Rietschel; Kathrin Scherer; Regina Treudler; Franziska Ruëff
Journal:  Dtsch Arztebl Int       Date:  2014-05-23       Impact factor: 5.594

7.  Characteristics of anaphylaxis in children referred to a tertiary care center.

Authors:  Emine Vezir; Mustafa Erkoçoğlu; Ayşenur Kaya; Müge Toyran; Celal Özcan; Ayşegül Akan; Dilek Azkur; Tayfur Giniş; Ersoy Civelek; Can Naci Kocabaş
Journal:  Allergy Asthma Proc       Date:  2013 May-Jun       Impact factor: 2.587

8.  Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis.

Authors:  Brian E Grunau; Jennifer Li; Tae Won Yi; Robert Stenstrom; Eric Grafstein; Matthew O Wiens; R Robert Schellenberg; Frank Xavier Scheuermeyer
Journal:  Ann Emerg Med       Date:  2013-11-13       Impact factor: 5.721

9.  Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization.

Authors:  Kari Bohlke; Robert L Davis; Frank DeStefano; S Michael Marcy; M Miles Braun; Robert S Thompson
Journal:  J Allergy Clin Immunol       Date:  2004-03       Impact factor: 10.793

Review 10.  The epidemiology of anaphylaxis in Europe: a systematic review.

Authors:  S S Panesar; S Javad; D de Silva; B I Nwaru; L Hickstein; A Muraro; G Roberts; M Worm; M B Bilò; V Cardona; A E J Dubois; A Dunn Galvin; P Eigenmann; M Fernandez-Rivas; S Halken; G Lack; B Niggemann; A F Santos; B J Vlieg-Boerstra; Z Q Zolkipli; A Sheikh
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

View more
  11 in total

Review 1.  Outpatient Emergencies: Anaphylaxis.

Authors:  Scott P Commins
Journal:  Med Clin North Am       Date:  2017-03-02       Impact factor: 5.456

2.  Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.

Authors:  Rachel L Miller; Maria Shtessel; Lacey B Robinson; Aleena Banerji
Journal:  J Allergy Clin Immunol       Date:  2019-06-24       Impact factor: 10.793

Review 3.  α-Gal and other recent findings that have informed our understanding of anaphylaxis.

Authors:  Jeffrey M Wilson; Thomas A E Platts-Mills
Journal:  Ann Allergy Asthma Immunol       Date:  2019-11-28       Impact factor: 6.347

4.  TPC1 deficiency or blockade augments systemic anaphylaxis and mast cell activity.

Authors:  Elisabeth Arlt; Marco Fraticelli; Volodymyr Tsvilovskyy; Wiebke Nadolni; Andreas Breit; Thomas J O'Neill; Stefanie Resenberger; Gunther Wennemuth; Christian Wahl-Schott; Martin Biel; Christian Grimm; Marc Freichel; Thomas Gudermann; Norbert Klugbauer; Ingrid Boekhoff; Susanna Zierler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-13       Impact factor: 11.205

5.  Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?

Authors:  Marco Caminati; Gabriella Guarnieri; Gianenrico Senna
Journal:  Vaccines (Basel)       Date:  2021-01-11

Review 6.  Effect of Nitric Oxide Pathway Inhibition on the Evolution of Anaphylactic Shock in Animal Models: A Systematic Review.

Authors:  Maryam Alfalasi; Sarah Alzaabi; Linda Östlundh; Rami H Al-Rifai; Suhail Al-Salam; Paul Michel Mertes; Seth L Alper; Elhadi H Aburawi; Abdelouahab Bellou
Journal:  Biology (Basel)       Date:  2022-06-16

7.  Cardiac Arrest Induced by an Anaphylactic Reaction Associated With the First Dose of Cetuximab.

Authors:  Atsuya Hane; Asami Ito; Ken Ishikura; Hiroshi Imai; Yoshinaga Okugawa
Journal:  Cureus       Date:  2022-06-26

8.  Risk factors of anaphylaxis in Korea: Identifying drug-induced anaphylaxis culprits using big data.

Authors:  Kyung-Min Ahn; Byung-Keun Kim; Min-Suk Yang
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

9.  A Case Report of Lifesaving Intravenous Bolus Epinephrine Administration in a Case of Severe Refractory Anaphylactic Shock.

Authors:  Mustafa Hammad; Noora Adam; Khurram Sarfaraz; Maryam Adam; Naser Mansoor
Journal:  Cureus       Date:  2022-08-22

10.  Pilot Project of Special Emergency Medical Service Team for Anaphylaxis in Gangwon-do, Korea: Results from an Online Questionnaire Survey.

Authors:  Hyeonseung Lee; Jae-Woo Kwon; Yong Whi Jeong; Changhoon Lee; Jeongmin Lee
Journal:  J Korean Med Sci       Date:  2021-11-01       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.